Galectin-3 in cancer

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 185-191

  Song, Lin ^a   Tang, Jian wu ^a   Owusu, Lawrence ^a   Sun, Ming Zhong ^a   Wu, Jun ^a   Zhang, Jun ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Expression; Galectin 3 (Gal 3); Location; Mechanism

Indexed keywords

GALECTIN 3; TUMOR MARKER;

BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOBLASTOMA; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MOLECULAR PATHOLOGY; MUTATION; NASOPHARYNX CARCINOMA; NONHUMAN; OVARY METASTASIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; STOMACH CANCER; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; PROGNOSIS;

GALECTIN 3; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896701371     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.019     Document Type: Review

References (116)

1. Houzelstein D., Gonçalves I.R., Fadden A.J., et al. Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 2004, 21(7):1177-1187.
2. Menon R.P., Hughes R.C. Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999, 264(2):569-576.
3. Gong H.C., Honjo Y., Nangia-Makker P., et al. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999, 59(24):6239-6245.
4. Nangia-Makker P., Wang Y., Raz T., et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010, 127(11):2530-2541.
5. Mazurek N., Byrd J.C., Sun Y., Ueno S., Bresalier R.S. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 2011, 117(19):4375-4380.
6. Kim S.J., Shin J.Y., Cheong T.C., et al. Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer. Clin Exp Metastasis 2011, 28(8):743-750.
7. Srinivasan N., Bane S.M., Ahire S.D., Ingle A.D., Kalraiya R.D. Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J 2009, 26(4):445-456.
8. O'Driscoll L., Linehan R., Liang Y.H., Joyce H., Oglesby I., Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res 2002, 22(6A):3117-3125.
9. Baldus S.E., Zirbes T.K., Weingarten M., et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 2000, 21(5):258-266.
10. Radosavljevic G., Jovanovic I., Majstorovic I., et al. Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis 2011, 28(5):451-462.
11. Prieto V.G., Mourad-Zeidan A.A., Melnikova V., et al. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 2006, 12(22):6709-6715.
12. Shibata T., Noguchi T., Takeno S., Takahashi Y., Fumoto S., Kawahara K. Impact of nuclear galectin-3 expression on histological differentiation and vascular invasion in patients with esophageal squamous cell carcinoma. Oncol Rep 2005, 13(2):235-239.
13. Califice S., Castronovo V., Bracke M., van den BrÛle F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23(45):7527-7536.
14. van den BrÛle F.A., Waltregny D., Liu F.T., Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000, 89(4):361-367.
15. Puglisi F., Minisini A.M., Barbone F., et al. Galectin-3 expression in non-small cell lung carcinoma. Cancer Lett 2004, 212(2):233-239.
16. Inohara H., Raz A. Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994, 11(6):527-532.
17. Liang Y., Li H., Hou S.C., et al. The expression of galectin-3 and osteopontin in occult metastasis of non-small cell lung cancer. Zhonghua Wai Ke Za Zhi 2009, 47(14):1061-1063.
18. Kapucuoglu N., Basak P.Y., Bircan S., Sert S., Akkaya V.B. Immunohistochemical galectin-3 expression in non-melanoma skin cancers. Pathol Res Pract 2009, 205(2):97-103.
19. Vereecken P., Zouaoui Boudjeltia K., Debray C., et al. High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 2006, 31(1):105-109.
20. Matsuda Y., Yamagiwa Y., Fukushima K., Ueno Y., Shimosegawa T. Basic hepatology (human study). Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008, 38(11):1098-1111.
21. D'Haene N., Catteau X., Maris C., Martin B., Salmon I., Decaestecker C. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br J Haematol 2008, 140(4):402-410.
22. Fukumori T., Oka N., Takenaka Y., et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006, 66(6):3114-3119.
23. Sanchez-Ruderisch H., Fischer C., Detjen K.M., et al. Tumor suppressor p16INK4a: downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 2010, 277(17):3552-3563.
24. Kobayashi T., Shimura T., Yajima T., et al. Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis 2011, 28(4):367.
25. Xie L., Ni W.K., Chen X.D., et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 2012, 138(6):1035-1043.
26. Song S., Ji B., Ramachandran V., et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012, 7(8):e42699.
27. Hann A., Gruner A., Chen Y., Gress T.M., Buchholz M. Comprehensive analysis of cellular galectin-3 reveals no consistent oncogenic function in pancreatic cancer cells. PLoS One 2011, 6(6):e20859.
28. Merlin J., Stechly L., de Beaucé S., et al. Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 2011 Jun 2, 30(22):2514-2525.
29. Kobayashi T., Shimura T., Yajima T., et al. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer 2011 Dec 15, 129(12):2775-2786.
30. Gaida M.M., Bach S.T., Günther F., et al. Expression of galectin-3 in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2012, 18(2):299-307.
31. Jiang H.B., Xu M., Wang X.P. Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J Gastroenterol 2008, 14(13):2023-2028.
32. Mohafez O.M.M., Abd El-Aziz M.A., Abd El-Ghany A.A. The expression pattern of galectin-3 in the rat hepatocellular carcinoma. Bull Pharm Sci 2012, 35:97-98.
33. Matsuda Y., Yamagiwa Y., Fukushima K., Ueno Y., Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008, 38(11):1098-1111.
34. Nakanishi Y., Tsuneyama K., Nomoto K., et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res 2008, 38(12):1241-1251.
35. Hsu D.K., Dowling C.A., Jeng K.C., Chen J.T., Yang R.Y., Liu F.T. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81(4):519-526.
36. Clark M.C., Pang M., Hsu D.K., et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012, 120(23):4635-4644.
37. D'Haene N., Maris C., Sandras F., et al. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int J Immunopathol Pharmacol 2005, 18(3):431-443.
38. Kim S.J., Lee S.J., Sung H.J., et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol 2008, 120(4):211-216.
39. Acikalin M.F., Etiz D., Gurbuz M.K., Ozudogru E., Canaz F., Colak E. Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma. Med Oncol 2012, 29(2):742-749.
40. Shi Y.H., He B.A., Kuchenbecker K.M., et al. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes P-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 2007, 121(6):1175-1181.
41. Nakamura M., Inufusa H., Adachi T., et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 1999, 15(1):143-148.
42. Legendre H., Decaestecker C., Nagy N., et al. Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol 2003, 16(5):491-504.
43. Shi Y., He B., Kuchenbecker K.M., et al. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 2007, 121(6):1175-1181.
44. Endo K., Kohnoe S., Tsujita E., et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer. Anticancer Res 2005, 25(4):3117-3121.
45. Tsuboi K., Shimura T., Masuda N., et al. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 2007, 27(4B):2289-2296.
46. Barrow H., Rhodes J.M., Yu L.G. Simultaneous determination of serum galectin-3 and -4 levels detects metastases in colorectal cancer patients. Cell Oncol (Dordr) 2013, 36(1):9-13.
47. Arfaoui-Toumi A., Kria-Ben Mahmoud L., Ben Hmida M., Khalfallah M.T., Regaya-Mzabi S., Bouraoui S. Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bull Cancer 2010, 97(2):E1-E8.
48. Straube T., Elli A.F., Greb C., et al. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011, 30(1):1-10.
49. Merseburger A.S., Kramer M.W., Hennenlotter J., et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 2008, 26(6):637-642.
50. Kaneko N., Gotoh A., Okamura N., et al. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 2013 May, 20(5):530-535.
51. Sakaki M., Fukumori T., Fukawa T., et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010, 57(1-2):152-157.
52. Ornellas A.A. Editorial comment to Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 2013, 20(5):535-536.
53. François C., van Velthoven R., De Lathouwer O., et al. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol 1999, 112(2):194-203.
54. Tomoharu F., Natsuo O., Hirofumi I., Masayuki T., Hiro-omi K. Galectin-3 is overexpressed in renal cell carcinoma and it regulates immune suppression through the induction of apoptosis of T cells. J Urol 2008, 179(4Suppl):91-92.
55. Miyazaki J., Hokari R., Kato S., et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 2002, 9(6):1307-1312.
56. Cheng C.S., Dong W.G., Luo H.S., Yu B.P. Expression of galectin-3 in gastric carcinoma and its significance. Chin J Cancer Res 2004, 16(3):3.
57. Yang Z.M., Wu X.T., He T., Da M.X., Luo T., Qian K. Expression of galectin-3 mRNA in gastric cancer with peritoneal metastasis. Sichuan Da Xue Xue Bao Yi Xue Ban 2006, 37(1):105-108.
58. Braeuer R.R., Zigler M., Kamiya T., et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 2012, 72(22):5757-5766.
59. Wang Y.G., Kim S.J., Baek J.H., Lee H.W., Jeong S.Y., Chun K.H. Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med 2012, 44(6):387-393.
60. Buljan M., Šitum M., Tomas D., Milošević M., Krušlin B. Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 2011, 25(10):1174-1181.
61. Vereecken P., Awada A., Suciu S., et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 2009, 19(5):316-320.
62. Pocza P., Süli-Vargha H., Darvas Z., Falus A. Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor. Int J Cancer 2008, 122(9):1972-1980.
63. Vereecken P., Debray C., Petein M., et al. Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 2005, 296(8):353-358.
64. van den BrÛle F.A., Buicu C., Sobel M.E., Liu F.T., Castronovo V. Galectin-3, a laminin binding protein, fails to modulate adhesion of human melanoma cells to laminin. Neoplasma 1995, 42(5):215-219.
65. van den BrÛle F.A., Liu F.T., Castronovo V. Transglutaminase-mediated oligomerization of galectin-3 modulates human melanoma cell interactions with laminin. Cell Adhes Commun 1998, 5(6):425-435.
66. Brown E.R., Doig T., Anderson N., et al. Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer 2012, 48(6):865-874.
67. Debray C., Vereecken P., Belot N., et al. Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 2004, 325(4):1393-1398.
68. Castronovo V., Van Den BrÛle F.A., Jackers P., et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996, 179(1):43-48.
69. Song Y.K., Billiar T.R., Lee Y.J. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 2002, 160(3):1069-1075.
70. Amm H.M., Buchsbaum D.J. Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer. Expert Rev Anticancer Ther 2011, 11(8):1193-1196.
71. Moisa A., Fritz P., Eck A., et al. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 2007, 27(4B):2131-2139.
72. Shekhar M.P., Nangia-Makker P., Tait L., Miller F., Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 2004, 165(6):1931-1941.
73. Mayoral M.A., Mayoral C., Meneses A., et al. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Invest 2008, 26(6):615-623.
74. Nangia-Makker P., Raz T., Tait L., Hogan V., Fridman R., Raz A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007 Dec 15, 67(24):11760-11768.
75. Balan V., Nangia-Makker P., Schwartz A.G., et al. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res 2008 Dec 15, 68(24):10045-10050.
76. Vandenbrule F., Bellahcene A., Jackers P., Liu F., Sobel M., Castronovo V. Antisense galectin-3 alters thymidine incorporation in human MDA-MB435 breast cancer cells. J Oncol 1997 Aug, 11(2):261-264.
77. Choi J.H., Chun K.H., Raz A., Lotan R. Inhibition of N-(4-hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3. Cancer Biol Ther 2004 May, 3(5):447-452.
78. Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. J Oncol 1998, 12(6):1287-1290.
79. John C.M., Leffler H., Kahl-Knutsson B., Svensson I., Jarvis G.A. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 2003, 9(6):2374-2383.
80. Baptiste T.A., James A., Saria M., Ochieng J. Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res 2007 Feb 15, 313(4):652-664.
81. Nangia-Makker P., Sarvis R., Visscher D.W., Bailey-Penrod J., Raz A., Sarkar F.H. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998 May, 49(2):171-183.
82. Kim H.R., Lin H.M., Biliran H., Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999, 59(16):4148-4154.
83. Honjo Y., Nangia-Makker P., Inohara H., Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001 Mar, 7(3):661-668.
84. Zhu W.Q., Ochieng J. Rapid release of intracellular galectin-3 from breast carcinoma cells by fetuin. Cancer Res 2001, 61(5):1869-1873.
85. Moon B.K., Lee Y.J., Battle P., Jessup J.M., Raz A., Kim H.R. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 2001, 159(3):1055-1060.
86. Shalom-Feuerstein R., Cooks T., Raz A., Kloog Y. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005, 65(16):7292-7300.
87. Kim S.J., Shin J.Y., Lee K.D., et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 2011, 6(9):e25103.
88. Asgarian-Omran H., Forghani P., Hojjat-Farsangi M., et al. Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia. Cancer Invest 2010, 28(7):717-725.
89. Ose R., Oharaa O., Nagase T. Galectin-1 and galectin-3 mediate protocadherin-24-dependent membrane localization of β-catenin in colon cancer cell line HCT116. Curr Chem Genomics 2012, 6:18-26.
90. Kim Y.S., Jung J.A., Kim H.J., et al. Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 2011, 404(1):96-102.
91. Wu K.L., Huang E.Y., Jhu E.W., et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol 2013, 48(3):350-359.
92. Yoo B.C., Hong S.H., Ku J.L., et al. Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci 2009, 66(2):350-364.
93. Wang Y., Nangia-Makker P., Balan V., Hogan V., Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis 2010, 1:e101.
94. Glinskii O.V., Sud S., Mossine V.V., et al. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia 2012, 14(1):65-73.
95. Knapp J.S., Lokeshwar S.D., Vogel U., et al. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol 2013, 31(2):351-358.
96. Wang Y., Nangia-Makker P., Tait L., et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009, 174(4):1515-1523.
97. Guha P., Kaptan E., Bandyopadhyaya G., et al. Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A 2013, 110(13):5052-5057.
98. Merseburger A.S., Kramer M.W., Hennenlotter J., et al. Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 2008, 68(1):72-77.
99. Ellerhorst J.A., Stephens L.C., Nguyen T., Xu X.C. Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 2002, 50(1):64-70.
100. Pacis R.A., Pilat M.J., Pienta K.J., et al. Decreased galectin-3 expression in prostate cancer. Prostate 2000, 44(2):118-123.
101. Ellerhorst J., Nguyen T., Cooper D.N., Lotan D., Lotan R. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999, 14(2):217-224.
102. Ellerhorst J., Troncoso P., Xu X.C., Lee J., Lotan R. Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 1999, 27(5):362-367.
103. Kim S.J., Choi I.J., Cheong T.C., et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010, 138(3):1035.
104. Okada K., Shimura T., Suehiro T., Mochiki E., Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 2006, 26(2B):1369-1376.
105. Dong W.G., Yu Q.F., Xu Y., Fan L.F. Li-cadherin is inversely correlated with galectin-3 expression in gastric cancer. Dig Dis Sci 2008, 53(7):1811-1817.
106. Cheong T.C., Shin J.Y., Chun K.H. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents 2010, 101(1):94-102.
107. Eliaz I. The role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol 2013, 6(2):343-349.
108. Buttery R., Monaghan H., Salter D.M., Sethi T. Galectin-3: differential expression between small-cell and non-small-cell lung cancer. Histopathology 2004, 44(4):339-344.
109. Choi J.H., Lim H.Y., Park J.S., et al. Expression of galectin-3 in non-small cell lung cancer (NSCLC): prognostic significance in adenocarcinoma. J Clin Oncol 2005, 23(16Suppl):9671.
110. Abdel-Aziz H.O., Murai Y., Takasaki I., et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J Cancer Res Clin Oncol 2008, 134(7):777-788.
111. El-Jawahri A.R., Lautenschlaeger T., Patel D., Chakravarti A. Role of galectin-3 in the activation of p-ERK and in resistance to radiotherapy in glioblastoma through the activation of p-ERK independent of Ras activity. J Clin Oncol 2009, 27(15Suppl):11073.
112. Cheng Y.L., Huang W.C., Chen C.L., et al. Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 2011, 412(2):334-340.
113. Yamamoto-Sugitani M., Kuroda J., Ashihara E., et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2011, 108(42):17468-17473.
114. Liu T.Y., Chen C.Y., Tien H.F., Lin C.W. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009, 54(2):214-220.
115. Hoyer K.K., Pang M., Gui D., et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 2004, 164(3):893-902.
116. Song L., Mao J., Zhang J., M.M., Li L.H., Tang J.W. Annexin A7 and its binding protein galectin-3 influence mouse hepatocellular carcinoma cell line in vitro. Biomed Pharmacother 2014, (in press; available online 2013 Dec. 2).